Rationale and design of the GUIDE-IT study: Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure.
about
A Test in Context: Critical Evaluation of Natriuretic Peptide Testing in Heart FailureState of the Art: Newer biomarkers in heart failureB-type natriuretic peptide-guided treatment for heart failure.Natriuretic Peptides as Biomarkers for Congestive States: The Cardiorenal Divergence.Model-based cost-effectiveness analysis of B-type natriuretic peptide-guided care in patients with heart failure.Personalized treatment of heart failure with biomarker guidance using a novel disease severity score.The vulnerable phase after hospitalization for heart failure.Effect of Natriuretic Peptide-Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.NT-proBNP and Echocardiographic Parameters for Prediction of Cardiovascular Outcomes in Patients with CKD Stages G2-G4.The Current and Potential Clinical Relevance of Heart Failure Biomarkers.Using biomarkers to guide heart failure management.Heart failure trials on pharmacological therapy in 2015: lessons learned and future outlook.Clinical Phenotyping of Heart Failure with Biomarkers: Current and Future Perspectives.Resetting the neurohormonal balance in heart failure (HF): the relevance of the natriuretic peptide (NP) system to the clinical management of patients with HFRemote Monitoring to Reduce Heart Failure Readmissions.Can Natriuretic Peptides be Used to Guide Therapy?Multimodality assessment and treatment of chemotherapy-induced cardiotoxicity.Do we need another heart failure biomarker: focus on soluble suppression of tumorigenicity 2 (sST2).Association between cardiac, renal, and hepatic biomarkers and outcomes in patients with acute heart failure.Heart failure with reduced ejection fraction.Multi-Biomarker Profiling and Recurrent Hospitalizations in Heart Failure.Association between Survival Time and Changes in NT-proBNP in Cats Treated for Congestive Heart Failure.Natriuretic peptide and cardiovascular risk: is it about "U"?Contemporary roles of registries in clinical cardiology: when do we need randomized trials?Influence of atrial fibrillation on post-discharge natriuretic peptide trajectory and clinical outcomes among patients hospitalized for heart failure: insights from the ASTRONAUT trial.Daily home BNP monitoring in heart failure for prediction of impending clinical deterioration: results from the HOME HF study.Novel Wearable Seismocardiography and Machine Learning Algorithms Can Assess Clinical Status of Heart Failure Patients.MicroRNAs in Heart Failure, Cardiac Transplantation, and Myocardial Recovery: Biomarkers with Therapeutic Potential.Synthesis, secretion, function, metabolism and application of natriuretic peptides in heart failure.Handling Missing Data in Within-Trial Cost-Effectiveness Analysis: A Review with Future Recommendations.Dynamic Changes in High-Sensitivity Cardiac Troponin I Are Associated with Dynamic Changes in Sum Absolute QRST Integral on Surface Electrocardiogram in Acute Decompensated Heart Failure.Natriuretic Peptides in Older Patients With Heart Failure: A Look Into the Seeds of Time.Real-world dosing of evidence-based medications for heart failure: embracing guideline recommendations and clinical judgement.Novel concept to guide systolic heart failure medication by repeated biomarker testing-results from TIME-CHF in context of predictive, preventive, and personalized medicine.Continuous biomarker monitoring by particle mobility sensing with single molecule resolution.Effect of prespecified therapy escalation on plasma NT-proBNP concentrations in dogs with stable congestive heart failure due to myxomatous mitral valve disease
P2860
Q26770151-843E39BB-BF54-45BC-B842-24031CBA486EQ27027899-38060727-4A0E-401A-8148-811000091E58Q30238936-7CD313B0-E439-46D6-B92A-BA25C39EEFB4Q33862358-415B0CC4-BD08-4876-94D1-F446C2D137FEQ37576886-B5E12466-ECC7-4988-AF29-05C642AA91ADQ37699042-F50798CE-3C0B-49FA-A499-AEE1F3772F22Q38349760-A601F9F5-2CEF-4E23-9B4E-3400C668EAABQ38371833-AF923F40-862F-4607-8EE4-F2DB55BC49ABQ38378152-62EB44C8-356A-43FE-8A73-C945319F19E0Q38568205-E1D85831-36AC-450A-898E-2DCC14C16065Q38613842-CA23B093-5C3B-4B68-A849-66E9DCEDEAC2Q38754215-3BB26B7D-4ADA-41B6-8897-7C98A6F1B6DCQ38756838-474EC97B-4C31-4824-8D38-97EA4DEEBB46Q38854043-68C05C4E-ADED-4329-A8AA-20886E09A5DFQ38953625-F857D21A-9344-44A2-8974-9731DFD64409Q38967512-2576B394-536D-4C0D-AE74-4A0F84EAA175Q38978044-89B326EB-3C22-4907-9263-9F5026E64C67Q39059489-CD14DC85-C8B0-4A80-8D7B-0A3464FD0D54Q39689820-9AC77552-9888-479E-BBF5-4E963792E055Q40081533-83732193-712A-4BF0-9D1B-9A17E91F718FQ41381124-D73EDFA4-FAA6-4C5F-B6F5-3917E1C14204Q42260678-32352DD7-9472-4149-B7F0-618A7E345375Q43228079-6419F08D-83BA-4B7D-B3A7-DCD10B393CBEQ45894982-35645E80-919A-4D53-8F2A-2FE3D19F521BQ46005004-150B78E5-B225-4299-AFFE-45949B969BC1Q47191187-4B2F8426-FBFC-46F2-ABE4-F2C49F192A8AQ47564062-70C13C01-0E4B-443C-AB8C-ED7DE545561AQ47644374-8AA11016-35A7-4316-B1C0-02D597A14760Q47855200-034E54F5-F93E-4BC9-83C8-EC93A7D99B0FQ50016205-28C65F06-0458-4F12-A3AD-91CB93F58CC9Q50890696-C25B4863-9B78-4413-88CF-61C9BADD6530Q50905395-9E639BB0-24C9-472D-84D4-3A73F08EE323Q53121367-847949EE-2BF0-4F74-91D5-94E6CD88B4B4Q55409538-ED014076-7924-4191-BCDD-70914B976955Q55452015-1871477D-2289-4C6E-A5D1-07165E484D35Q58738210-0F446964-7CAC-457F-B930-FD2B5498FF1D
P2860
Rationale and design of the GUIDE-IT study: Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure.
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Rationale and design of the GU ...... ed Treatment in Heart Failure.
@ast
Rationale and design of the GU ...... ed Treatment in Heart Failure.
@en
Rationale and design of the GU ...... ed Treatment in Heart Failure.
@nl
type
label
Rationale and design of the GU ...... ed Treatment in Heart Failure.
@ast
Rationale and design of the GU ...... ed Treatment in Heart Failure.
@en
Rationale and design of the GU ...... ed Treatment in Heart Failure.
@nl
prefLabel
Rationale and design of the GU ...... ed Treatment in Heart Failure.
@ast
Rationale and design of the GU ...... ed Treatment in Heart Failure.
@en
Rationale and design of the GU ...... ed Treatment in Heart Failure.
@nl
P2093
P2860
P50
P1433
P1476
Rationale and design of the GU ...... ed Treatment in Heart Failure.
@en
P2093
David J Whellan
Eric S Leifer
G Michael Felker
Gayle Paynter
Ileana L Piña
Kirkwood F Adams
Lawton S Cooper
Mona Fiuzat
Nancy Houston-Miller
Patrice Desvigne-Nickens
P2860
P304
P356
10.1016/J.JCHF.2014.05.007
P577
2014-09-03T00:00:00Z